TY -的T1 tubercul的筛查和治疗osis among pregnant women in Stockholm 2016–2017 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00851-2019 SP - 1900851 AU - Fröberg, Gabrielle AU - Jansson, Lena AU - Nyberg, Katherine AU - Obasi, Birgitta AU - Westling, Katarina AU - Berggren, Ingela AU - Bruchfeld, Judith Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/01/03/13993003.00851-2019.abstract N2 - Swedish National tuberculosis (TB) guidelines recommend screening of active and latent TB (LTBI) among pregnant women (PW) from high endemic countries or previous exposure to possibly improve early detection and treatment.We evaluated cascade of care of a newly introduced TB screening program of PW in Stockholm county 2016–2017. The algorithm included clinical data and Quantiferon® (QFT) at the Maternal Health Care clinics and referral for specialist care upon positive test or TB symptoms.About 29 000 HIV negative PW were registered yearly, where of 11% originated from high-endemic countries. In 2016, 72% of these were screened with Quantiferon® (QFT), of which 22% were QFT positive and 85% were referred for specialist care. In 2017, corresponding figures were 64%, 19% and 96%. LTBI treatment rate among all QFT positive PW increased from 24% to 37% over time. Treatment completion with mainly rifampicin postpartum was 94%. Of the 69 registered HIV positive PW, 78% originated from high-endemic countries. Of these, 72% where screened with QFT and 15% were positive, but none was treated for LTBI. Nine HIV negative active pulmonary TB cases were detected (incidence 215/100 000). None had been screened for TB prior to pregnancy and only one had sought care due to symptoms.Systematic TB screening of PW in Stockholm was feasible with high yield of unknown LTBI and mostly asymptomatic active TB. Optimised routines improved referrals to specialist care. Treatment completion of LTBI was very high. Our findings justify TB screening of this risk group for early detection and treatment.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Fröberg has nothing to disclose.Conflict of interest: Dr. Jansson has nothing to disclose.Conflict of interest: Dr. Nyberg has nothing to disclose.Conflict of interest: Dr. Obasi has nothing to disclose.Conflict of interest: Dr. Westling has nothing to disclose.Conflict of interest: Dr. Berggren has nothing to disclose.Conflict of interest: Dr. Bruchfeld has nothing to disclose. ER -